|
PRPF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.33066907387547E-15 |
| Normal-vs-Stage2 |
1.46649999921422E-08 |
| Normal-vs-Stage3 |
5.15587572635923E-13 |
| Normal-vs-Stage4 |
3.3603000382243E-09 |
| Stage1-vs-Stage2 |
7.598200E-01 |
| Stage1-vs-Stage3 |
2.680800E-01 |
| Stage1-vs-Stage4 |
5.502400E-01 |
| Stage2-vs-Stage3 |
6.640600E-01 |
| Stage2-vs-Stage4 |
8.439000E-01 |
| Stage3-vs-Stage4 |
8.399400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
1.031630E-04 |
| Normal-vs-Asian |
1.83209999999878E-05 |
| Caucasian-vs-AfricanAmerican |
2.017400E-01 |
| Caucasian-vs-Asian |
3.370200E-02 |
| AfricanAmerican-vs-Asian |
7.851200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.32736094022357E-12 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
9.551600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
1.45119471994803E-11 |
| Normal-vs-Age(61-80Yrs) |
4.99000840648023E-12 |
| Normal-vs-Age(81-100Yrs) |
8.0275000000074E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.467400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.495800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.957000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.416610E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.705400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.440400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.49679999950081E-07 |
| Classical-VS-Follicular |
2.552800E-01 |
| Classical-VS-Other |
9.319400E-01 |
| Classical-VS-Normal |
1.65523150741365E-12 |
| Tall-VS-Follicular |
2.858800E-03 |
| Tall-VS-Other |
1.506180E-01 |
| Tall-VS-Normal |
1.62458935193399E-12 |
| Follicular-VS-Other |
7.725400E-01 |
| Follicular-VS-Normal |
1.42860001606238E-09 |
| Other-VS-Normal |
6.323700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.4166445794217E-13 |
| Normal-vs-N1 |
2.44119999770476E-08 |
| N0-vs-N1 |
8.439000E-01 |
|
|
